Vaccination with Dukoral against travelers' diarrhea (ETEC) and cholera.
There is currently only one vaccine available that provides protection against diarrhea caused by Vibrio cholerae and, to a lesser degree, enterotoxigenic Escherichia coli (ETEC). Adverse events of this oral whole-cell/recombinant B-subunit vaccine have been negligible. Protective efficacy against cholera is 85%, while protection against the heat-labile toxin of ETEC reaches 67%. There is still a need for data on protection of Western travelers against travelers' diarrhea in general by Dukoral vaccination. However, current studies show a protective effect of up to 43%. Although the vaccine is only licensed for vaccination against cholera in most Western countries, there is mounting evidence that the oral cholera vaccine is a valuable option to those traveling to high-risk endemic areas. Vaccination against cholera and ETEC should be recommended for at-risk travelers, in particular those with high exposure at their travel destination or high personal risks through fluid loss.
Jelinek
Tomas
T
Berlin Center for Travel & Tropical Medicine, Berlin, Germany. jelinek@bctropen.de
Kollaritsch
Herwig
H
D001428:Bacterial Vaccines; D022121:Cholera Vaccines / Q000276:immunology / Q000627:therapeutic use*; D003967:Diarrhea / Q000276:immunology / Q000517:prevention & control*; D054307:Enterotoxigenic Escherichia coli / Q000472:pathogenicity*; D004927:Escherichia coli Infections / Q000276:immunology / Q000517:prevention & control*; D022361:Escherichia coli Vaccines / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D007115:Immunization Schedule; D014195:Travel; D014611:Vaccination
D001428:Bacterial Vaccines; D022121:Cholera Vaccines; C586175:Dukoral; D022361:Escherichia coli Vaccines